Diagnosis | Size (mm) | T/B* before toremifene | T/B* after toremifene† | Pgp‡ | |||
---|---|---|---|---|---|---|---|
20 min | 120 min | 20 min | 120 min | C494 | C219 | ||
G2 ILC/IDC | 30 | 1.65 | 1.99 | 1.35 | 1.81 | 0 | 0 |
G2 IDC | 24 | NV | NV | NA | NA | 3 | 3 |
G1 IDC | 20 | 1.51 | 1.26 | 1.52 | 1.46 | 2 | 2 |
G3 IDC | 27 | 1.76 | 1.63 | 1.65 | 1.36 | 3 | 3 |
G1 IDC | 15 | 1.81 | 1.89 | 1.9 | 1.79 | 1 | 0.5 |
G2 IDC | 17 | 1.84 | 1.64 | 1.71 | 1.61 | 1 | 0 |
G1 IDC | 16 | NV | NV | NV | NV | 3 | 2 |
G3 IDC | 10 | 2.2 | 2.9 | 3.26 | 2.67 | 0 | 0 |
G3 IDC | 20 | 1.72 | 0.64 | NA | NA | 2 | 1 |
G3 IDC | 14 | NV | NV | NV | NV | 3 | 3 |
G3 IDC | 14 | NV | NV | NV | NV | 3 | 2 |
G3 IDC | 25 | 2.05 | 1.62 | 2.17 | 1.81 | 3 | 3 |
G2 IDC | 23 | 2.24 | 2.34 | 2.05 | 2.04 | 0 | 0 |
G2 IDC | 37 | 2.25 | 1.52 | 2.44 | 1.53 | 3 | 3 |
G2 ILC | 45 | 2.29 | 1.94 | 2.58 | 2.11 | 2 | 3 |
G1 IDC | 30 | 2.68 | 2.65 | 2.04 | 1.99 | 0 | 0 |
G1 IDC | 40 | 2.53 | 1.99 | 2.22 | 1.96 | 1 | 1 |
G2 IDC | 15 | 2.53 | 2.98 | NA | NA | 0 | 0 |
G3 IDC | 25 | 1.41 | 1.21 | 1.52 | 1.27 | 2 | 2 |
G2 IDC | 14 | 1.23 | 1.32 | 1.41 | 1.19 | 1 | 1 |
↵* T/B 20 or 120 min after injection of radiotracer.
↵† Three days after high-dose toremifene treatment.
↵‡ Pgp expression in tumor determined by immunohistochemistry with monoclonal antibodies C494 and C219 (0, no expression; 1, slight expression; 2, moderate expression; 3, strong expression).
G1, G2, G3 = well, moderately, and poorly differentiated, respectively; ILC = intralobular carcinoma; IDC = intraductal carcinoma; NV = not visible; NA = not available.